Thursday, May 12, 2016
6:00 p.m.-7:30 p.m.

Opening Plenary Session
Coquina North

Welcome from the chairpersons
Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Opening remarks from the lead supporters
Julie M. Fleshman, Pancreatic Cancer Action Network
Kerri Kaplan, Lustgarten Foundation

Perspective from a patient
Anne Glauber

Opening keynote address: Title to be announced
Chairperson: Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York
Andrew V. Biankin, University of Glasgow, Glasgow, Scotland

7:30 p.m.-9:00 p.m.

Opening Reception
Coquina South

Friday, May 13, 2016
7:30 a.m.-8:30 a.m.

Breakfast and Mentoring Roundtables
Valencia Terrace

8:30 a.m.-10:15 a.m.

Plenary Session 1: Epidemiology and Risk Factors
Coquina North
Chairperson: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Identification of familial pancreatic cancer susceptibility genes
Nicholas J. Roberts, Johns Hopkins University, Baltimore, Maryland

Genetic and non-genetic risk factors of pancreatic cancer
Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, Minnesota
Pancreatic cancer etiology: Digging into the unknown
Núria Malats, Spanish National Cancer Center (CNIO), Madrid, Spain

Patients with severe chronic pancreatitis contain widespread and numerous pancreatic cancer-related somatic variants as detected by picodroplet-enabled targeted sequencing*
Robert W. Cowan, University of Michigan, Ann Arbor, Michigan

10:15 a.m.-10:45 a.m. Break
Coquina South

10:45 a.m.-11:45 p.m. Plenary Session 2: Early Detection
Coquina North
Chairperson: To be announced

Evolving insight into the tumor stroma and exosomes for detection and treatment of pancreatic cancer
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, Texas

Serum contains enough information for early detection of pancreatic cancer
Carl Borrebaeck, Lund University, Lund, Sweden

11:45 a.m.-2:45 p.m. Lunch (on own)

2:45 p.m.-4:30 p.m. Plenary Session 3: Innovations and New Directions in Pancreatic Cancer Therapy
Coquina North
Chairperson: Channing J. Der, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Drugging undruggable KRAS: will MYC do the trick?
Channing J. Der, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Role of stereotactic body radiation therapy in patients with locally advanced and borderline resectable pancreas cancer
Joseph M. Herman, Johns Hopkins University, Baltimore, Maryland

Tumor metabolism and early metabolic response predicts survival of metastatic pancreatic cancer patients treated with FOLFIRINOX chemotherapy*
Do-Youhn Oh, Seoul National University Hospital, Seoul, Republic of Korea
Mutant p53 promotes adenocarcinoma in pancreatic ductal cells*

Jennifer M. Bailey, The University of Texas Health Science Center, Houston, Texas

Nrf2 promotes mRNA translation in pancreatic cancer*

Iok In Christine Chio, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

4:30 p.m.-5:00 p.m.  Break
Coquina South

5:00 p.m.-6:00 p.m.  Keynote Address
Coquina North
Chairperson: Robert H. Vonderheide, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

Biomarker selected therapy for pancreas ductal adenocarcinoma: An emerging reality?
Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, New York, New York

6:00 p.m.-9:00 p.m.  Poster Session A and Reception
Coquina South

Saturday, May 14, 2016
7:30 a.m.-8:30 a.m.  Breakfast and Mentoring Roundtables
Valencia Terrace

8:30 a.m.-10:30 a.m.  Plenary Session 4: Preclinical Drug Development for Pancreatic Cancer
Coquina North
Chairperson: David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Pancreatic cancer biology and medicine
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Applications of PDX models in preclinical PDAC drug development
Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Stromal regulation and therapeutic targeting of the pancreatic cancer epigenome
Mara H. Sherman, Salk Institute for Biological Studies, La Jolla, California
Genome-scale CRISPR-Cas9 screening to identify essential genes and pathways in pancreatic cancer*
Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts

A novel β2 adrenergic-nerve growth factor feed forward loop promotes pancreatic cancer*
Bernhard W. Renz, University of Munich, Munich, Germany

10:30 a.m.-11:00 a.m. Break
Coquina South

11:00 a.m.-1:00 p.m. Plenary Session 5: Heterogeneity of Pancreatic Cancer
Coquina North
Chairperson: Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York

Heterogeneity of pancreatic cancer genomes: New insights
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York

Deconstructing pancreatic cancer
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

Reconstructing compartment-specific regulatory programs in pancreatic cancer
Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, New York

The global phospho-proteome of K-Ras mutant cells and tissues
Kevin M. Haigis, Beth Israel Deaconess Medical Center, Boston, Massachusetts

1:00 p.m.-4:00 p.m. Poster Session B and Lunch
Coquina South

4:00 p.m.-6:15 p.m. Plenary Session 6: Molecular Drivers of Pancreatic Cancer Biology and Metastasis
Coquina North
Chairperson: Ben Z. Stanger, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

Probing tumor heterogeneity with mouse models
Ben Z. Stanger, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

Defining the balance between division and dissemination in pancreas cancer
Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA

Biological drivers of pancreatic cancer

Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York

Deconstructing p53 transcriptional networks in pancreatic cancer suppression*

Laura D. Attardi, Stanford University, Stanford, CA

Hypoxia-induced Blimp1 expression induces a transient metastatic heterogeneity in pancreatic cancer*

Monte M. Winslow, Stanford University School of Medicine, Stanford, CA

Loss of SIRT6 reactivates the RNA-binding protein Lin28b to drive pancreatic cancer*

Sita Kugel, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Sunday, May 15, 2016

7:30 a.m.-8:30 a.m. Breakfast and Mentoring Roundtables
Valencia Terrace

8:30 a.m.-10:30 a.m. Plenary Session 7: Immune Drug Development
Coquina North
Chairperson: Marina Pasca Di Magliano, University of Michigan, Ann Arbor, Michigan

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immune-suppressive environment in pancreatic cancer

Marina Pasca Di Magliano, University of Michigan, Ann Arbor, Michigan

Reprogramming the tumor microenvironment to improve responses to immunotherapy

David G. DeNardo, Washington University School of Medicine, St. Louis, Missouri

Immune landscape of human pancreatic cancer

Robert H. Vonderheide, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

CXCR2 inhibition suppresses metastasis and improves the response to immunotherapy in pancreatic cancer*
Jennifer P. Morton, Cancer Research UK Beatson Institute, Glasgow, United Kingdom

_Dual CCR2/CXCR2 chemokine receptor blockade prevents tumor compensatory myeloid recruitment in pancreatic cancer_*

Timothy M. Nywening, Washington University, St. Louis, Missouri

10:30 a.m.-11:00 a.m.  Break
Coquina South

11:00 a.m.-1:00 p.m.  **Plenary Session 8: Big Picture/Wrap-up Panel Discussion**
Coquina North

Moderator:
Robert H. Vonderheide, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

Panelists:
Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Jonathan R. Brody, Thomas Jefferson University, Philadelphia, Pennsylvania
Lynn Matrisian, Pancreatic Cancer Action Network, Manhattan Beach, California
Allyson J. Ocean, Weill Cornell Medical Center, New York, New York

Q&A

1:00 p.m.  **Closing Remarks and Departure**

*Short talks from proffered abstracts*